ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / PLSE / options
NVST (46) IRTC (47) ICUI (56) ATRC (63) ⌘ Pro Terminal β†’

Pulse Biosciences Inc (PLSE) Options Positioning, Max Pain & Unusual Sweeps

$52.90 +1.26% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $52.92

Pulse Biosciences Inc (PLSE) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $3.73B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PLSE Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is PLSE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Pulse Biosciences Inc (NASDAQ: PLSE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $52.90 (+1.26% 1D, market cap $3.73B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PLSE ranks #479 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does PLSE compare to NVST and IRTC in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), PLSE carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -30.7%. By comparison, NVST (Envista Holdings Corporation) holds a D grade (46/100 RQD, P/E 84.1x, ROIC 5.1%, cap $3.78B) and IRTC (iRhythm Holdings Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -13.5%, cap $4.07B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PLSE?
β–Ό

Per PLSE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001625101), Pulse Biosciences Inc generated $350.0K in revenue (-99.8% YoY), -$72.8M in net income, and -$54.4M in free cash flow against $94.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $52.92 (+0.04%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (39/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510039
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D-
Cash (6)Whales (14)SEC (8)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.5% Base Target
$62 Bull$48 Base$38 Bear
πŸ“¬ FREE PLSE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for PLSE)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (39/100 Composite)
πŸ” WHY PLSE SCORES 39/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+14/20 pts (36% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
31
Grade E$48.54+4.7% Next Q
Q2 (-2Q)
34
Grade E$50.84+4.6% Next Q
Q3 (-1Q)
36
Grade E$53.20-0.6% Next Q
Current
39
Grade D-$52.90-7.6% Hist 90D Ξ±
Trajectory: E (31) β†’ D- (39)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a PLSE Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While PLSE currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($51.24) and Max Pain ($55.55) forces dealer call-delta covering toward $61.84.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PLSEβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œPLSE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 39%NO 61%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PLSE)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PLSE.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PLSE)

  • βœ“Walkthrough of PLSE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
PLSE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +164.10%β–² ASCENDING CHANNEL
2026-11-03O $55.48H $55.48L $52.24C $52.90VOL 466.5K
RES: $76.85SUP: $46.66SMA50: $51.24SMA200: $31.75
$61.82$49.73$37.64$25.55$13.46RES $76.85SUP $46.66$52.902026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PLSE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ PLSE Butterfly Map β†’ + Track PLSE β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -99.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PLSE today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for PLSE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PLSE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PLSE)

Health Care Rank #479 of 1015 βš”οΈ NVST vs PLSE Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (PLSE vs. NVST, IRTC, ICUI, ATRC)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Pulse Biosciences Inc (PLSE) ranks #479 by composite RQD confidence (39/100, grade D-) and #186 by equity capitalization ($3.73B). Within this direct 5-issuer industry benchmark cohort, NVST leads on earnings valuation at 84.1x trailing P/E, while NVST leads on capital efficiency and profitability with 5.1% ROIC and 54.7% gross margin. ATRC currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with PLSE at 39/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PLSE ACTIVE
Pulse Biosciences Inc
D- 39/100 β€” -30.0% -30.7% +1.26% $3.73B Benchmark Subject
NVST
Envista Holdings Corporation
D 46/100 84.1x 54.7% 5.1% +5.10% $3.78B /nvst-vs-plse β†’
IRTC
iRhythm Holdings Inc.
D 47/100 β€” 70.6% -13.5% +2.27% $4.07B /irtc-vs-plse β†’
ICUI
ICU Medical Inc.
D+ 56/100 β€” 36.8% 1.0% -0.85% $4.10B /icui-vs-plse β†’
ATRC
AtriCure Inc.
C 63/100 β€” 75.0% -1.9% -2.24% $3.12B /atrc-vs-plse β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001625101 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pulse Biosciences Inc (PLSE) reported GAAP revenue of $350.0K (-99.8% vs. FY2024 revenue of $157.5M , and -99.7% cumulative change since FY2023) , GAAP net income of -$72.8M, operating cash flow of -$54.1M, and free cash flow of -$54.4M (-49.3% YoY). On the balance sheet, PLSE closed FY2025 with $94.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $350.0K -$72.8M -$54.1M -$54.4M $94.5M β€”
FY2024 (FY) 2024-12-31 $157.5M -$53.6M -$36.3M -$36.5M $132.5M β€”
FY2023 (FY) 2023-12-31 $122.0M -$42.2M -$33.0M -$33.0M β€” β€”

3. PLSE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PLSE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Pulse Biosciences Inc (NASDAQ: PLSE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $52.90 (+1.26% 1D, market cap $3.73B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PLSE ranks #479 in composite RQD confidence.

How does PLSE compare to NVST and IRTC in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PLSE carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -30.7%. By comparison, NVST (Envista Holdings Corporation) holds a D grade (46/100 RQD, P/E 84.1x, ROIC 5.1%, cap $3.78B) and IRTC (iRhythm Holdings Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -13.5%, cap $4.07B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PLSE?

Per PLSE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001625101), Pulse Biosciences Inc generated $350.0K in revenue (-99.8% YoY), -$72.8M in net income, and -$54.4M in free cash flow against $94.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PLSE trading relative to its 50-day, 200-day, and 52-week technical levels?

PLSE last traded at $52.90 (+1.26% on volume of 250,456 shares), positioning the stock +3.24% above its 50-day simple moving average ($51.24) and +66.61% above its 200-day simple moving average ($31.75). Across its 52-week range of $12.56 to $58.90, PLSE sits at the 87.1% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($46.29 to $59.51).

Direct Sub-Reports: PLSE RQD Cockpit PLSE 12M Forecast PLSE Earnings & Move PLSE Dividends & DRIP PLSE Insiders & 13F PLSE Whale Options PLSE Profit Sankey PLSE News & Why
ROARABLE RATING BRIEF β€’ RQD 39/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

PLSE β€” Pulse Biosciences Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Pulse Biosciences Inc (PLSE) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $52.90 (+1.26% 1D, market capitalization $3.73B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -30.7%, gross margin of -30.0%, operating margin of -60.0%, and free cash flow yield of -1.38%.
  • Whale 13F & Options Flow (14/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Pulse Biosciences Inc (PLSE) is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry.3M for FY 2025 . Its sector and industry classification places it within medical instrument manufacturing.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Pulse Biosciences Inc (PLSE) reported $350.0K in annual revenue (up from $157.5M in FY2024, -99.8% YoY) and -$72.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($122.0M revenue, -$42.2M net income) through FY2025, PLSE scaled operating cash flow to -$54.1M and free cash flow to -$54.4M, backed by $94.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -1.38% and institutional whale pillar of 14/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $12.56 – $58.90 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), PLSE carries a macro regime beta of 1.00 and gross margin of -30.0%.

  • Key Question #1: Can PLSE sustain or expand its -60.0% operating margin and -30.7% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $350.0K and free cash flow of -$54.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PLSE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PLSE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pulse Biosciences Inc (PLSE) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to PLSE Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PLSE Bull vs. Bear Conversation Board β€” What's Your Call at $52.90?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PLSE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PLSE:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER β€’ Verified $100K Arena Trader πŸ‚ BULLISH 🎯 Target: $68.43 (+31.0%)
πŸ“Œ Pinned Debate

Institutional accumulation and options positioning score 16 / 20, the strongest pillar, with a 52-week high of $58.9 and a price of 55.

Don't sleep on PLSE's setup in Health Care. Institutional accumulation and options positioning score 16 / 20, the strongest pillar, with a 52-week high of $58.9 and a price of 55.48 after a 3.37% gain.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (39/100) backs up the fundamental quality.

SectorRotator πŸ‚ BULL

@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (-30.0%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER β€’ Forensic Short Bias 🐻 BEARISH 🎯 Target: $42.84 (-18.0%)
Spot @ $52.24

ROIC of -30.7%, FCF of -$54.4M in FY 2025, and cash down to $80.7M from $118.0M leave the company with weak cash generation and limited

Here is the bear case nobody on the bull side wants to address on PLSE: ROIC of -30.7%, FCF of -$54.4M in FY 2025, and cash down to $80.7M from $118.0M leave the company with weak cash generation and limited balance-sheet resilience.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE